Comparative Pharmacology
Head-to-head clinical analysis: PEDIAPRED versus PREDNISONE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAPRED versus PREDNISONE INTENSOL.
PEDIAPRED vs PREDNISONE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisolone is a glucocorticoid receptor agonist that binds to the intracellular glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune responses by reducing lymphocyte proliferation and activity.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Oral: 5-60 mg/day as a single dose or divided doses; adjust based on condition and response.
5-60 mg orally once daily or divided twice daily, titrated to response.
None Documented
None Documented
2.5–3.5 hours (terminal) in children; clinical context: requires multiple daily doses for sustained effect.
2-4 hours (terminal) for prednisone; prednisolone half-life 2-4 hours. Clinical context: shorter than anti-inflammatory effect due to delayed receptor-mediated action.
Renal: ~80% as metabolites (mainly glucuronides and sulfates) and <5% unchanged; fecal: ~15%.
Renal: <30% unchanged; major metabolites (prednisolone, 20-dihydroprednisolone) conjugated and excreted in urine. Fecal: <10%.
Category C
Category D/X
Corticosteroid
Corticosteroid